Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors
申请人:Bienayme Hugues
公开号:US20090042876A1
公开(公告)日:2009-02-12
The present invention relates to inhibitors of protein kinases of formula I:
which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.
[EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
申请人:ASTRAZENECA AB
公开号:WO2009081197A1
公开(公告)日:2009-07-02
The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.
BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155
申请人:Bradbury Robert Hugh
公开号:US20100016279A1
公开(公告)日:2010-01-21
The invention concerns bicyclic compounds of Formula I
wherein the integers X
1
, X
2
, X
3
, Ring A, R
4
, R
5
and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.
Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
申请人:AstraZeneca AB
公开号:US08003649B2
公开(公告)日:2011-08-23
The invention concerns bicyclic compounds of Formula I
wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.